SCHEMBL17676271

SCHEMBL17676271

CN(C)c1cnc2ccc(Nc3ccccc3)nc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 5/20 0.46
▸ PDGFRA P16234 5/20 0.46
▸ MAPK1 P28482 5/20 0.43
▸ MAPT P10636 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ IKBKB O14920 1/20 0.43
▸ AURKA O14965 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ PDPK1 O15530 1/20 0.43
▸ CHEK2 O96017 1/20 0.43
▸ PRKCG P05129 1/20 0.43
▸ CDK1 P06493 1/20 0.43
▸ LYN P07948 1/20 0.43
▸ KIT P10721 1/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ FGFR1 P11362 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ RPS6KB1 P23443 1/20 0.43
▸ CDK2 P24941 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20306100 0.78 PDGFRB (0.50) PDGFRBPDGFRAMAPK1MAPTRAB9A
SCHEMBL5759348 0.77 MAPK1 (0.53) PDGFRBPDGFRAMAPK1MAPTRAB9A
SCHEMBL4340922 0.75 MAPK1 (0.53) MAPK1PIK3CAMAPK14MAPK8MAPK9
SCHEMBL16125091 0.74 PDGFRB (0.46) PDGFRBPDGFRAMAPK1MAPTRAB9A
SCHEMBL16125096 0.74 ALDH1A1 (0.51) PDGFRBPDGFRAMAPK1MAPTRAB9A
SCHEMBL20305884 0.73 MAPT (0.52) PDGFRBPDGFRAMAPK1MAPTRAB9A
SCHEMBL3637143 0.73 PIK3CA (0.55) PDGFRBPDGFRAMAPK1RAB9ANPC1
SCHEMBL4357137 0.71 PIK3CA (0.55) MAPK1PIK3CAMAPK14MAPK8MAPK9
SCHEMBL5757148 0.71 LMNA (0.52) PDGFRBMAPK1MAPTRAB9ANPC1
SCHEMBL4697024 0.71 MAPK1 (0.56) PDGFRBPDGFRAMAPK1ATMPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10004733-B2 — — 2018-06-26 — — US disclosed
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2016-08-18 — — US disclosed
US-9309242-B2 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2016-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10004733-B2 — SDHB, SDHA, NDUFS5 PDGFRB 1274/4885PDGFRA 1727/4885MAPK1 2681/4885
US-20160235744-A1 SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS FGFR1, FGFR2, FGFR3 PDGFRB 14/4885PDGFRA 30/4885MAPK1 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback